CD14+CD16+ and CD14+CD163+ monocyte subpopulations in kidney allograft transplantation

BMC Immunology

Table 1 Demographic characteristics at the time of transplantation

	No induction		rATG		Basiliximab		P-value
Number	25		28		18
Gender (male/female)	14/11		19/9		9/9		n.s.^b
Recipient age (years)	57,9	[27.7; 73.3]	52,9	[21.5; 78.6]	52,9	[25.6; 67.1]	n.s.^d
Donor age (years)	52.0	[16.0; 68.0]	46.5	[22.0; 74.0]	63.5	[46.0; 75.0]	<0.001^d,e
^aHLA MM	3	[1; 6]		[2; 5]		[1; 5]	n.s.^d
1st/2nd and 3rd T x R (n)	25/0		12/16		18/0		<0.0001^b
^aPRA (%)	4	[0; 36]	64	[0; 96]	7	[0; 44]	<0.0001^d,g
^aCNI (TAC/CsA)(n)	21/4		28/0		18/0		n.s.^b
^aCIT (hours)	15.2	[11.0; 20.7]	15.9	[7.7; 22.8]	17.6	[12.4; 21.0]	n.s.^d
Dialysis time (years)	2.0	[0.2; 9.42]	2.2	[0.5; 6.37]	2.1	[0; 4.9]	n.s.^d
Cause of renal failure							n.s.
Primary GN	10		10		5
Hereditary diseases	4		6		6
Diabetic or ischaemic nephropathy	8		2		5
^aTIN	2		3		1
^aANCA vasculitis or lupus nephritis	0		4		0
Other causes	1		3		1

^aANCA, anti-neutrophil cytoplasmic antibodies; CIT, cold ischaemic time; CNI, calcineurin inhibitor; CsA, cyclosporine A; GN, glomerulonephritis; HLA MM, HLA mismatch; PRA, historical panel reactive antibodies, measured every 3 months before transplantation, the highest number was considered in each patient; TAC, tacrolimus; TIN, tubulointerstitial nephritis; T 3, renal transplantation.
^bChi square test P-value.
^dKruskal–Wallis test P value.
^eDunn’s multiple comparison test: significant difference between the basiliximab group and the rATG or controls.
^gDunn’s multiple comparison test: significantp difference between rATG and the no induction or basiliximab groups.

ISSN: 1471-2172